Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin
regimen of MDI or CSII. Randomisation to 3 treatments arms (equal assignment) following a
screening period, an optimisation period and a run-in period. 52 week double-blind treatment
period, and 3 week follow-up period.